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Changes in body temperature are a characteristic
feature of sepsis. The study by Kushimoto and
colleagues in a recent issue of Critical Care
demonstrates that hypothermia is a very important
manifestation of infection associated with very high
mortality. Combined with recent data suggesting that
febrile patients with infections have the lowest
mortality risk, the study raises the question of whether
inducing therapeutic hyperthermia might be
beneficial in this patient group. Body temperature is
easily measured and manipulated in the ICU, and
interventional trials defining the most appropriate
temperature targets in ICU patients with infections are
urgently needed. One such study is in progress.for patients with sepsis occurs at a peak temperature inIntroduction
The majority of patients with diagnosed sepsis have a
fever; however, 10% to 20% of patients are hypothermic
[1–4]. The study by Kushimoto and colleagues in a recent
issue of Critical Care demonstrates that hypothermia is a
very important manifestation of infection [1]. In an in-
ception cohort study, the investigators studied 624
patients with severe sepsis and demonstrated that
those with a temperature of not more than 36.5°C
had higher illness severity scores, more disseminated
intravascular coagulation, and higher in-hospital and
28-day mortality rates than those with a temperature
of more than 36.5°C [1]. The risk of death at hospital
discharge and at 28 days for septic patients with
hypothermia was more than double that of patients
who were not hypothermic.* Correspondence: paul.young@ccdhb.org.nz
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Hypothermia in the context of infection may be a marker
of an impaired immune response to infection or a marker
of disease severity or both. Moreover, ‘cold sepsis’ may be
more difficult to identify, so that multi-organ failure may
be established by the time antibiotics are started. Although
it is now clear that sepsis patients who have a low body
temperature have an increased risk of death, it is not
known whether intervening to warm patients with ‘cold
sepsis’ is beneficial or not. Furthermore, if one were to
warm patients with ‘cold sepsis’, it is not clear whether the
appropriate target should be the restoration of normother-
mia or the induction of mild or moderate hyperthermia.
Our group’s previous data involving more than
500,000 patients and more than 300 ICUs in Australia
and New Zealand and the UK show that the lowest risk
the first 24 hours in the ICU of somewhere between
38°C and 39.4°C [2]. This observation suggests that
moderate therapeutic hyperthermia may be a rational
target in the treatment of cold sepsis and warrants
investigation.
The use of therapeutic hyperthermia to treat patients
with infections is not a new concept. In the early part of
the 20th century, therapeutic hyperthermia was used
successfully to treat syphilis [5] and gonorrhea [6]. This
approach contrasts with the approach investigated in the
recently published Sepsiscool Study [7]. In the Sepsiscool
Study, 200 febrile patients with septic shock requiring
vasopressors, mechanical ventilation, and sedation were
allocated to external cooling to achieve normothermia
for 48 hours or no external cooling. Fever control using
external cooling decreased vasopressor requirements
and appeared to delay death. External cooling of febrile
patients with septic shock to normothermia and external
warming of patients with hypothermia to mild or
moderate hyperthermia may seem paradoxical. Yet it is
conceivable that warming patients who fail to mount a
fever and cooling patients with high fever and significant
hypotension might both be useful strategies. A recently
published study investigating therapeutic hypothermia for
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early because of an increased risk of death in the patients
assigned to cooling, suggesting that, if cooling of febrile
patients with sepsis is undertaken, induced hypothermia
should be avoided [8]. However, beyond this, the current
evidence base is insufficient to guide practice.
Conclusions
Given that changes in body temperature are common in
patients with infections and that physical and pharmaco-
logical interventions are commonly used in the ICU [9,10],
clinical trials are overdue. With this in mind, a multicenter
randomized double-blind placebo controlled trial called
HEAT (permissive HyperthErmia through Avoidance of
paraceTamol in known or suspected infection in the ICU)
(registration: ACTRN12612000513819) is under way in
Australia and New Zealand [11]. The HEAT trial will
provide level 1 evidence on the safety and efficacy of using
paracetamol to treat elevated body temperature in ICU
patients with infections and will help us understand more
clearly whether it’s hot to be cool or cool to be hot.
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